keyword
https://read.qxmd.com/read/38562606/use-of-platelet-rich-plasma-on-in-vitro-maturation-during-bovine-embryo-production
#21
JOURNAL ARTICLE
Eduardo Baia de Souza, Diego Dubeibe Marin, Anelise Sarges Ramos, Bruno Porpino Homobono, Priscilla do Carmo de Azevedo Ramos, Vanessa Cunha de Brito, Gabriela Santos da Cruz, Nathalia Nogueira da Costa, Marcela da Silva Cordeiro, Simone do Socorro Damasceno Santos
One of the crucial aspects to be considered for successful in vitro production (IVP) of embryos is the composition of the various media used throughout the stages of this reproductive biotechnology. The cell culture media employed should fulfill the metabolic requirements of both gametes during oocyte maturation and sperm development, as well as the embryo during its initial cell divisions. Most IVP protocols incorporate blood serum into the media composition as a source of hormones, proteins, growth factors, and nutrients...
2024: Animal Reproduction
https://read.qxmd.com/read/38561335/comparison-studies-identify-mesenchymal-stromal-cells-with-potent-regenerative-activity-in-osteoarthritis-treatment
#22
JOURNAL ARTICLE
Hongshang Chu, Shaoyang Zhang, Zhenlin Zhang, Hua Yue, Huijuan Liu, Baojie Li, Feng Yin
Osteoarthritis affects 15% of people over 65 years of age. It is characterized by articular cartilage degradation and inflammation, leading to joint pain and disability. Osteoarthritis is incurable and the patients may eventually need joint replacement. An emerging treatment is mesenchymal stromal cells (MSCs), with over two hundred clinical trials being registered. However, the outcomes of these trials have fallen short of the expectation, due to heterogeneity of MSCs and uncertain mechanisms of action. It is generally believed that MSCs exert their function mainly by secreting immunomodulatory and trophic factors...
April 1, 2024: NPJ Regenerative Medicine
https://read.qxmd.com/read/38560897/donor-muse-cell-treatment-without-hla-matching-tests-and-immunosuppressant-treatment
#23
JOURNAL ARTICLE
Shinya Minatoguchi, Yasuyuki Fujita, Kuniyasu Niizuma, Teiji Tominaga, Toru Yamashita, Koji Abe, Mari Dezawa
The strength of stem cell therapy is the regeneration of tissues by synergistic pleiotropic effects. Among many stem cell types, mesenchymal stem cells (MSCs) that are comprised of heterogenous population are widely used for clinical applications with the expectation of pleiotropic bystander effects. Muse cells are pluripotent-like/macrophage-like stem cells distributed in the bone marrow, peripheral blood, and organ connective tissues as cells positive for the pluripotent surface marker stage-specific-embryonic antigen -3...
April 1, 2024: Stem Cells Translational Medicine
https://read.qxmd.com/read/38560893/influence-of-substrate-stiffness-on-ipsc-derived-retinal-pigmented-epithelial-cells
#24
JOURNAL ARTICLE
Rion J Wendland, Budd A Tucker, Kristan S Worthington
Retinal degenerative diseases are a major cause of blindness involving the dysfunction of photoreceptors, retinal pigmented epithelium (RPE), or both. A promising treatment approach involves replacing these cells via surgical transplantation, and previous work has shown that cell delivery scaffolds are vital to ensure sufficient cell survival. Thus, identifying scaffold properties that are conducive to cell viability and maturation (such as suitable material and mechanical properties) is critical to ensuring a successful treatment approach...
April 1, 2024: Stem Cells Translational Medicine
https://read.qxmd.com/read/38559257/a-trisomy-21-linked-hematopoietic-gene-variant-in-microglia-confers-resilience-in-human-ipsc-models-of-alzheimer-s-disease
#25
Mengmeng Jin, Ziyuan Ma, Rui Dang, Haiwei Zhang, Rachael Kim, Haipeng Xue, Jesse Pascual, Steven Finkbeiner, Elizabeth Head, Ying Liu, Peng Jiang
While challenging, identifying individuals displaying resilience to Alzheimer's disease (AD) and understanding the underlying mechanism holds great promise for the development of new therapeutic interventions to effectively treat AD. Down syndrome (DS), or trisomy 21, is the most common genetic cause of AD. Interestingly, some people with DS, despite developing AD neuropathology, show resilience to cognitive decline. Furthermore, DS individuals are at an increased risk of myeloid leukemia due to somatic mutations in hematopoietic cells...
March 14, 2024: bioRxiv
https://read.qxmd.com/read/38558362/advances-in-organoid-technology-a-focus-on-corneal-limbal-organoids
#26
REVIEW
Chuwei Lu, Qihua Le
Organoid technology provides a versatile platform for simulating organogenesis, investigating disease pathogenesis, and exploring therapeutic interventions. Among various types of organoids that have been developed, corneal limbal organoids, the three-dimensional miniaturized corneas which are derived from either pluripotent stem cells or limbal epithelial stem cells, are particularly promising for clinical translation. This narrative review summarized the state-of-the-art in corneal limbal organoids research including the cultivation methods, clinical relevance and its limitations and challenges...
April 1, 2024: Stem cell reviews and reports
https://read.qxmd.com/read/38557027/decellularized-brain-extracellular-matrix-hydrogel-aids-the-formation-of-human-spinal-cord-organoids-recapitulating-the-complex-three-dimensional-organization
#27
JOURNAL ARTICLE
Weidong Wu, Youjun Liu, Renfeng Liu, Yuhao Wang, Yuqi Zhao, Hui Li, Botao Lu, Cheng Ju, Xinlin Gao, Hailiang Xu, Yulin Cao, Shixiang Cheng, Zhiyuan Wang, Shuaijun Jia, Chunping Hu, Lei Zhu, Dingjun Hao
The intricate electrophysiological functions and anatomical structures of spinal cord tissue render the establishment of in vitro models for spinal cord-related diseases highly challenging. Currently, both in vivo and in vitro models for spinal cord-related diseases are still underdeveloped, complicating the exploration and development of effective therapeutic drugs or strategies. Organoids cultured from human induced pluripotent stem cells (hiPSCs) hold promise as suitable in vitro models for spinal cord-related diseases...
April 1, 2024: ACS Biomaterials Science & Engineering
https://read.qxmd.com/read/38555683/diagnosis-of-alpha-mannosidosis-practical-approaches-to-reducing-diagnostic-delays-in-this-ultra-rare-disease
#28
REVIEW
Lucia Santoro, Graziella Cefalo, Fabrizio Canalini, Silvia Rossi, Maurizio Scarpa
Alpha-mannosidosis is an ultra-rare lysosomal disease that is caused by variants of the MAN2B1 gene on chromosome 19p13. These variants result in faulty or absent alpha-mannosidase in lysosomes, which leads to intracellular accumulation of mannose-containing oligosaccharides. Diagnosis of alpha-mannosidosis is often delayed, in part because of the rarity of the disease, its gradual onset and heterogeneity of presentation, but also because of the similarity of many signs and symptoms of the disease to those of other lysosomal diseases...
March 14, 2024: Molecular Genetics and Metabolism
https://read.qxmd.com/read/38555547/addressing-cardiovascular-toxicity-risk-of-electronic-nicotine-delivery-systems-in-the-twenty-first-century-what-are-the-tools-needed-for-the-job-and-do-we-have-them
#29
REVIEW
Mark Chandy, Thomas Hill, Nerea Jimenez-Tellez, Joseph C Wu, S Emma Sarles, Edward Hensel, Qixin Wang, Irfan Rahman, Daniel J Conklin
Cigarette smoking is positively and robustly associated with cardiovascular disease (CVD), including hypertension, atherosclerosis, cardiac arrhythmias, stroke, thromboembolism, myocardial infarctions, and heart failure. However, after more than a decade of ENDS presence in the U.S. marketplace, uncertainty persists regarding the long-term health consequences of ENDS use for CVD. New approach methods (NAMs) in the field of toxicology are being developed to enhance rapid prediction of human health hazards. Recent technical advances can now consider impact of biological factors such as sex and race/ethnicity, permitting application of NAMs findings to health equity and environmental justice issues...
March 31, 2024: Cardiovascular Toxicology
https://read.qxmd.com/read/38548938/standardized-production-of-hpsc-derived-cardiomyocyte-aggregates-in-stirred-spinner-flasks
#30
REVIEW
Nils Kriedemann, Wiebke Triebert, Jana Teske, Mira Mertens, Annika Franke, Kevin Ullmann, Felix Manstein, Lika Drakhlis, Alexandra Haase, Caroline Halloin, Ulrich Martin, Robert Zweigerdt
A promising cell-therapy approach for heart failure aims at differentiating human pluripotent stem cells (hPSCs) into functional cardiomyocytes (CMs) in vitro to replace the disease-induced loss of patients' heart muscle cells in vivo. But many challenges remain for the routine clinical application of hPSC-derived CMs (hPSC-CMs), including good manufacturing practice (GMP)-compliant production strategies. This protocol describes the efficient generation of hPSC-CM aggregates in suspension culture, emphasizing process simplicity, robustness and GMP compliance...
March 28, 2024: Nature Protocols
https://read.qxmd.com/read/38546696/long-term-outcomes-and-renal-responses-following-autologous-hematopoietic-stem-cell-transplantation-for-light-chain-deposition-disease-a-retrospective-study-on-behalf-of-the-chronic-malignancies-working-party-of-the-european-society-for-blood-and-marrow-transplantation
#31
JOURNAL ARTICLE
Laurent Garderet, Luuk Gras, Linda Koster, Liesbeth De Wreede, Rovira Montserrat, Laure Vincent, Roland Fenk, Kamaraj Karunanithi, Dries Deeren, Martin Kaufmann, Jürgen Kuball, Hakan Ozdogu, Maria Jesus Pascual Cascon, Jakob Passweg, Adam Rye, Urpu Salmenniemi, John Snowden, Charlotte Toftmann Hansen, Xavier Leleu, Lauris Gastaud, Joanna Drozd Sokolowska, Kavita Raj, Meral Beksac, Stefan Schönland, Patrick Hayden, Donal McLornan
There is little long-term outcome data on the efficacy of autologous hematopoietic stem cell transplantation (ASCT) in light chain deposition disease (LCDD). We identified 51 LCDD patients in the EBMT registry who had undergone upfront ASCT between 1995 and 2021. The median serum creatinine was 280 μmol/L and 45% required renal replacement therapy (RRT) at time of transplant. The melphalan dose was 100mg/m2 in 23%, 140mg/m2 in 55% and 200 mg/m2 in 21%. The rate of very good partial response or better improved from 41% pre-transplant to 66% at Day +100 post-ASCT...
March 28, 2024: Haematologica
https://read.qxmd.com/read/38544564/the-future-of-beta-cells-replacement-in-the-era-of-regenerative-medicine-and-organ-bioengineering
#32
EDITORIAL
Ekaterine Berishvili, Andrea Peloso, Alice A Tomei, Andrew R Pepper
No abstract text is available yet for this article.
2024: Transplant International
https://read.qxmd.com/read/38540717/comparison-between-the-regenerative-and-therapeutic-impacts-of-bone-marrow-mesenchymal-stem-cells-and-adipose-mesenchymal-stem-cells-pre-treated-with-melatonin-on-liver-fibrosis
#33
JOURNAL ARTICLE
Ahmed Elzainy, Abir El Sadik, Waleed Mohammad Altowayan
BACKGROUND: The distinctive feature of liver fibrosis is the progressive replacement of healthy hepatic cells by the extracellular matrix protein, which is abundant in collagen I and III, with impaired matrix remodeling. The activation of myofibroblastic cells enhances the fibrogenic response of complex interactions of hepatic stellate cells, fibroblasts, and inflammatory cells to produce the excessive deposition of the extracellular protein matrix. This process is activated by multiple fibrogenic mediators and cytokines, such as TNF-α and IL-1β, accompanied with a decrease in the anti-fibrogenic factor NF-κβ...
March 1, 2024: Biomolecules
https://read.qxmd.com/read/38538275/the-role-of-human-pluripotent-stem-cells-in-amyotrophic-lateral-sclerosis-from-biological-mechanism-to-practical-implications
#34
REVIEW
Laura Ceccarelli, Lorenzo Verriello, Giada Pauletto, Mariarosaria Valente, Leopoldo Spadea, Carlo Salati, Marco Zeppieri, Tamara Ius
Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder, characterized by progressive loss of both upper and lower motor neurons, resulting in clinical features such as muscle weakness, paralysis, and ultimately, respiratory failure. Nowadays, there is not effective treatment to reverse the progression of the disease, that leads to death within 3-5 years after the onset. Nevertheless, the induced pluripotent stem cells (iPS) technology could be the answer, providing disease modelling, drug testing, and cell-based therapies for this pathology...
March 20, 2024: Frontiers in Bioscience (Landmark Edition)
https://read.qxmd.com/read/38534757/to-repair-a-broken-heart-stem-cells-in-ischemic-heart-disease
#35
REVIEW
Theodora M Stougiannou, Konstantinos C Christodoulou, Ioannis Dimarakis, Dimitrios Mikroulis, Dimos Karangelis
Despite improvements in contemporary medical and surgical therapies, cardiovascular disease (CVD) remains a significant cause of worldwide morbidity and mortality; more specifically, ischemic heart disease (IHD) may affect individuals as young as 20 years old. Typically managed with guideline-directed medical therapy, interventional or surgical methods, the incurred cardiomyocyte loss is not always completely reversible; however, recent research into various stem cell (SC) populations has highlighted their potential for the treatment and perhaps regeneration of injured cardiac tissue, either directly through cellular replacement or indirectly through local paracrine effects...
March 8, 2024: Current Issues in Molecular Biology
https://read.qxmd.com/read/38534402/transgene-free-cynomolgus-monkey-ipscs-generated-under-chemically-defined-conditions
#36
JOURNAL ARTICLE
Yuliia Tereshchenko, Nesil Esiyok, Enrique Garea-Rodríguez, Daniele Repetto, Rüdiger Behr, Ignacio Rodríguez-Polo
Non-human primates (NHPs) are pivotal animal models for translating novel cell replacement therapies into clinical applications, including validating the safety and efficacy of induced pluripotent stem cell (iPSC)-derived products. Preclinical development and the testing of cell-based therapies ideally comprise xenogeneic (human stem cells into NHPs) and allogenic (NHP stem cells into NHPs) transplantation studies. For the allogeneic approach, it is necessary to generate NHP-iPSCs with generally equivalent quality to the human counterparts that will be used later on in patients...
March 21, 2024: Cells
https://read.qxmd.com/read/38533650/experiences-of-patients-with-metachromatic-leukodystrophy-adrenoleukodystrophy-or-krabbe-disease-and-their-family-members-a-qualitative-systematic-review
#37
JOURNAL ARTICLE
Yuta Koto, Shingo Ueki, Miyae Yamakawa, Norio Sakai
OBJECTIVE: This review aimed to synthesize the experiences of patients with metachromatic leukodystrophy, adrenoleukodystrophy, or Krabbe disease and those of their families. INTRODUCTION: Leukodystrophies are metabolic diseases caused by genetic mutations. There are multiple forms of the disease, varying in age of onset and symptoms. The progression of leukodystrophies worsens central nervous system symptoms and significantly affects the lives of patients and their families...
March 28, 2024: JBI evidence synthesis
https://read.qxmd.com/read/38526281/cell-reprogramming-therapy-for-parkinson-s-disease
#38
JOURNAL ARTICLE
Wenjing Dong, Shuyi Liu, Shangang Li, Zhengbo Wang
Parkinson's disease is typically characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta. Many studies have been performed based on the supplementation of lost dopaminergic neurons to treat Parkinson's disease. The initial strategy for cell replacement therapy used human fetal ventral midbrain and human embryonic stem cells to treat Parkinson's disease, which could substantially alleviate the symptoms of Parkinson's disease in clinical practice. However, ethical issues and tumor formation were limitations of its clinical application...
November 1, 2024: Neural Regeneration Research
https://read.qxmd.com/read/38526280/emerging-strategies-for-nerve-repair-and-regeneration-in-ischemic-stroke-neural-stem-cell-therapy
#39
JOURNAL ARTICLE
Siji Wang, Qianyan He, Yang Qu, Wenjing Yin, Ruoyu Zhao, Xuyutian Wang, Yi Yang, Zhen-Ni Guo
Ischemic stroke is a major cause of mortality and disability worldwide, with limited treatment options available in clinical practice. The emergence of stem cell therapy has provided new hope to the field of stroke treatment via the restoration of brain neuron function. Exogenous neural stem cells are beneficial not only in cell replacement but also through the bystander effect. Neural stem cells regulate multiple physiological responses, including nerve repair, endogenous regeneration, immune function, and blood-brain barrier permeability, through the secretion of bioactive substances, including extracellular vesicles/exosomes...
November 1, 2024: Neural Regeneration Research
https://read.qxmd.com/read/38515710/bibliometric-analysis-of-global-research-on-human-organoids
#40
JOURNAL ARTICLE
Huanyu Li, Daofeng Wang, Cheong Wong Ho, Dan Shan
The emergence and rapid development of human organoids have provided the possibility to replace animal models in treating human diseases. Intelligence studies help focus on research hotspots and address key mechanistic issues. Currently, few comprehensive studies describe the characteristics of human organoid research. In this study, we extracted 8,591 original articles on organoids from the Web of Science core collection database over the past two decades and conducted intelligence analysis using CiteSpace...
March 30, 2024: Heliyon
keyword
keyword
22424
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.